Elicio Therapeutics (NASDAQ: ELTX) has opened a Phase 1 investigator-initiated trial evaluating its cancer immunotherapy ELI-002 7P in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE